Sumitomo Mitsui Trust Group Inc. Increases Stock Holdings in Catalent, Inc. (NYSE:CTLT)

Sumitomo Mitsui Trust Group Inc. raised its holdings in Catalent, Inc. (NYSE:CTLT - Free Report) by 3.7% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 405,318 shares of the company's stock after buying an additional 14,373 shares during the period. Sumitomo Mitsui Trust Group Inc. owned about 0.22% of Catalent worth $24,550,000 as of its most recent SEC filing.

A number of other institutional investors also recently bought and sold shares of the business. OVERSEA CHINESE BANKING Corp Ltd lifted its position in shares of Catalent by 18.8% during the 3rd quarter. OVERSEA CHINESE BANKING Corp Ltd now owns 6,242 shares of the company's stock worth $378,000 after buying an additional 988 shares during the last quarter. Wolverine Asset Management LLC lifted its position in Catalent by 9.1% in the third quarter. Wolverine Asset Management LLC now owns 46,685 shares of the company's stock valued at $2,828,000 after acquiring an additional 3,908 shares during the last quarter. Crossmark Global Holdings Inc. grew its holdings in shares of Catalent by 2.6% during the third quarter. Crossmark Global Holdings Inc. now owns 9,133 shares of the company's stock worth $553,000 after purchasing an additional 229 shares during the last quarter. Olympiad Research LP increased its position in shares of Catalent by 93.2% during the third quarter. Olympiad Research LP now owns 33,009 shares of the company's stock worth $1,999,000 after purchasing an additional 15,924 shares in the last quarter. Finally, Sentry Investment Management LLC purchased a new stake in shares of Catalent in the 3rd quarter valued at about $53,000.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on CTLT. Robert W. Baird restated a "neutral" rating and set a $63.50 price target on shares of Catalent in a research note on Tuesday, September 24th. William Blair restated a "market perform" rating on shares of Catalent in a research report on Tuesday, September 3rd. Baird R W downgraded shares of Catalent from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, September 24th. Finally, StockNews.com raised shares of Catalent from a "sell" rating to a "hold" rating in a research report on Thursday. Eight analysts have rated the stock with a hold rating, According to MarketBeat, Catalent has an average rating of "Hold" and an average target price of $63.40.

Catalent Stock Performance

Shares of NYSE CTLT traded up $0.19 during mid-day trading on Friday, hitting $59.10. 1,488,223 shares of the company were exchanged, compared to its average volume of 1,875,772. The stock has a 50 day simple moving average of $59.84 and a 200-day simple moving average of $58.21. Catalent, Inc. has a 1-year low of $36.74 and a 1-year high of $61.20. The company has a quick ratio of 1.96, a current ratio of 2.51 and a debt-to-equity ratio of 1.38. The firm has a market cap of $10.73 billion, a price-to-earnings ratio of -26.15, a price-to-earnings-growth ratio of 2.35 and a beta of 1.16.

Catalent (NYSE:CTLT - Get Free Report) last released its earnings results on Tuesday, November 5th. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of $0.05 by ($0.18). Catalent had a negative return on equity of 0.66% and a negative net margin of 9.28%. The firm had revenue of $1.02 billion during the quarter, compared to analyst estimates of $1.06 billion. During the same quarter last year, the business posted ($0.10) EPS. The firm's revenue was up 4.2% on a year-over-year basis. On average, sell-side analysts forecast that Catalent, Inc. will post 0.84 EPS for the current fiscal year.

Insider Buying and Selling at Catalent

In related news, Director Michelle R. Ryan sold 2,800 shares of the firm's stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $59.70, for a total value of $167,160.00. Following the completion of the sale, the director now owns 10,835 shares in the company, valued at $646,849.50. This trade represents a 20.54 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider David Mcerlane sold 1,994 shares of the business's stock in a transaction dated Thursday, September 26th. The stock was sold at an average price of $59.97, for a total transaction of $119,580.18. Following the sale, the insider now directly owns 36,304 shares in the company, valued at approximately $2,177,150.88. This represents a 5.21 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 5,114 shares of company stock valued at $305,931. 0.31% of the stock is owned by corporate insiders.

Catalent Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.